Genitourinary Cancer News

SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.

SAN FRANCISCO — Transurethral resection of bladder tumor followed by systemic therapy induced stringently defined clinical complete response among more than 40% of patients with muscle-invasive bladder cancer, according to phase 2 study results.

High BMI appeared associated with increased risk for any-grade immune-related adverse events among a cohort of patients with advanced cancer undergoing treatment with immune checkpoint inhibitors.

Only 30% of individuals with neuroendocrine tumors rank living longer as their single top priority in treating their cancer, according to a study conducted by researchers at City of Hope.

Patient withdrawal from cancer clinical trials can result in systematic bias, insufficiently powered studies and a loss of valuable scientific knowledge, according to a study in JAMA Network Open.

Nearly 3 years after the COVID-19 pandemic propelled telehealth from the fringes of cancer care to the mainstream, research into the use of this technology across oncology remains limited.

William Kevin Kelly, DO, has been appointed chair of the department of medical oncology for Sidney Kimmel Medical College at Thomas Jefferson University.

In a scientific statement, the American Heart Association issued guidance on the epidemiology, diagnosis and management of cancer therapy-induced hypertension.

Black and Hispanic patients with cancer and caregivers appeared more likely than their white counterparts to report at least one negative care experience, according to study results.

Response rates to investigational therapies evaluated in NCI-sponsored phase 1 trials for solid cancers have doubled over the past 2 decades, according to study results published in The Lancet.